142 related articles for article (PubMed ID: 37954812)
1. 40-Gene Expression Profile Representative of Metastatic Risk of Squamous Cell Carcinoma in a Mohs Surgical Patient.
Slater KN; Ryder E; Gomez-Meade C
Cureus; 2023 Oct; 15(10):e46853. PubMed ID: 37954812
[TBL] [Abstract][Full Text] [Related]
2. The Prognostic Value and Clinical Utility of the 40-Gene Expression Profile (40-GEP) Test in Cutaneous Squamous Cell Carcinoma: Systematic Review and Meta-Analysis.
Masarwy R; Shilo S; Carmel Neiderman NN; Kampel L; Horowitz G; Muhanna N; Mansour J
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173922
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling for metastatic risk in head and neck cutaneous squamous cell carcinoma.
Arron ST; Wysong A; Hall MA; Bailey CN; Covington KR; Kurley SJ; Goldberg MS; Kasprzak JM; Somani AK; Ibrahim SF; Brodland DG; Cleaver NJ; Maher IA; Xia Y; Koyfman SA; Newman JG
Laryngoscope Investig Otolaryngol; 2022 Feb; 7(1):135-144. PubMed ID: 35155791
[TBL] [Abstract][Full Text] [Related]
4. Integrating the 40-Gene Expression Profile (40-GEP) Test Improves Metastatic Risk-Stratification Within Clinically Relevant Subgroups of High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients.
Wysong A; Somani AK; Ibrahim SF; Cañueto J; Fitzgerald AL; Siegel JJ; Prasai A; Goldberg MS; Farberg AS; Regula C; Bar A; Kasprzak J; Brodland DG; Koyfman SA; Arron ST
Dermatol Ther (Heidelb); 2024 Mar; 14(3):593-612. PubMed ID: 38424384
[TBL] [Abstract][Full Text] [Related]
5. Long-term clinical outcomes of patients with invasive cutaneous squamous cell carcinoma treated with Mohs micrographic surgery: A 5-year, multicenter, prospective cohort study.
Tschetter AJ; Campoli MR; Zitelli JA; Brodland DG
J Am Acad Dermatol; 2020 Jan; 82(1):139-148. PubMed ID: 31279037
[TBL] [Abstract][Full Text] [Related]
6. Impact of Gene Expression Profile Testing on the Management of Squamous Cell Carcinoma by Dermatologists.
Rebeca T; Giselle P; Litchman GH; Rigel DS
J Drugs Dermatol; 2019 Oct; 18(10):980-984. PubMed ID: 31584775
[TBL] [Abstract][Full Text] [Related]
7. Validation of four cutaneous squamous cell carcinoma staging systems using nationwide data.
Venables ZC; Tokez S; Hollestein LM; Mooyaart AL; van den Bos RR; Rous B; Leigh IM; Nijsten T; Wakkee M
Br J Dermatol; 2022 May; 186(5):835-842. PubMed ID: 34862598
[TBL] [Abstract][Full Text] [Related]
8. Integrating gene expression profiling into NCCN high-risk cutaneous squamous cell carcinoma management recommendations: impact on patient management.
Farberg AS; Hall MA; Douglas L; Covington KR; Kurley SJ; Cook RW; Dinehart SM
Curr Med Res Opin; 2020 Aug; 36(8):1301-1307. PubMed ID: 32351136
[No Abstract] [Full Text] [Related]
9. Validating 4 Staging Systems for Cutaneous Squamous Cell Carcinoma Using Population-Based Data: A Nested Case-Control Study.
Roscher I; Falk RS; Vos L; Clausen OPF; Helsing P; Gjersvik P; Robsahm TE
JAMA Dermatol; 2018 Apr; 154(4):428-434. PubMed ID: 29516080
[TBL] [Abstract][Full Text] [Related]
10. Clinical Utility of the 40-Gene Expression Profile (40-GEP) Test for Improved Patient Management Decisions and Disease-Related Outcomes when Combined with Current Clinicopathological Risk Factors for Cutaneous Squamous Cell Carcinoma (cSCC): Case Series.
Au JH; Hooper PB; Fitzgerald AL; Somani AK
Dermatol Ther (Heidelb); 2022 Feb; 12(2):591-597. PubMed ID: 34951694
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous squamous cell carcinoma staging may influence management in users: A survey study.
Patel VA; McCullum C; Sparks AD; Schmults CD; Arron ST; Jambusaria-Pahlajani A
Cancer Med; 2022 Jan; 11(1):94-103. PubMed ID: 34796670
[TBL] [Abstract][Full Text] [Related]
12. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention.
Stratigos AJ; Garbe C; Dessinioti C; Lebbe C; Bataille V; Bastholt L; Dreno B; Fargnoli MC; Forsea AM; Frenard C; Harwood CΑ; Hauschild A; Hoeller C; Kandolf-Sekulovic L; Kaufmann R; Kelleners-Smeets NW; Malvehy J; Del Marmol V; Middleton MR; Moreno-Ramirez D; Pellecani G; Peris K; Saiag P; van den Beuken-van Everdingen MHJ; Vieira R; Zalaudek I; Eggermont AMM; Grob JJ;
Eur J Cancer; 2020 Mar; 128():60-82. PubMed ID: 32113941
[TBL] [Abstract][Full Text] [Related]
13. Integrating 40-GEP Testing to Improve Clinical Recommendations for Adjuvant Radiation for Cutaneous Squamous Cell Carcinoma: Multidisciplinary Consensus Guidelines.
Gopal R; Marquardt M; Singh G; Tolkachjov SN; Arron ST
J Clin Aesthet Dermatol; 2024 Mar; 17(3 Suppl 2):S3-S8. PubMed ID: 38495846
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous Squamous Cell Carcinoma: A Review of High-Risk and Metastatic Disease.
Burton KA; Ashack KA; Khachemoune A
Am J Clin Dermatol; 2016 Oct; 17(5):491-508. PubMed ID: 27358187
[TBL] [Abstract][Full Text] [Related]
15. Improved cutaneous melanoma survival stratification through integration of 31-gene expression profile testing with the American Joint Committee on Cancer 8th Edition Staging.
Wisco OJ; Marson JW; Litchman GH; Brownstone N; Covington KR; Martin BJ; Quick AP; Siegel JJ; Caruso HG; Cook RW; Winkelmann RR; Rigel DS
Melanoma Res; 2022 Apr; 32(2):98-102. PubMed ID: 35254332
[TBL] [Abstract][Full Text] [Related]
16. Brigham and Women's Hospital tumor classification system for basal cell carcinoma identifies patients with risk of metastasis and death.
Morgan FC; Ruiz ES; Karia PS; Besaw RJ; Neel VA; Schmults CD
J Am Acad Dermatol; 2021 Sep; 85(3):582-587. PubMed ID: 33497751
[TBL] [Abstract][Full Text] [Related]
17. Comparison of tumor staging systems for cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia.
Inda JJ; Kabat BF; Larson MC; Slager SL; Baum CL
J Am Acad Dermatol; 2019 Mar; 80(3):639-645. PubMed ID: 30165169
[TBL] [Abstract][Full Text] [Related]
18. Comparing the eighth and the seventh editions of the American Joint Committee on Cancer staging system and the Brigham and Women's Hospital alternative staging system for cutaneous squamous cell carcinoma: Implications for clinical practice.
Cañueto J; Burguillo J; Moyano-Bueno D; Viñolas-Cuadros A; Conde-Ferreirós A; Corchete-Sánchez LA; Pérez-Losada J; Román-Curto C
J Am Acad Dermatol; 2019 Jan; 80(1):106-113.e2. PubMed ID: 30003984
[TBL] [Abstract][Full Text] [Related]
19. Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test.
Ibrahim SF; Kasprzak JM; Hall MA; Fitzgerald AL; Siegel JJ; Kurley SJ; Covington KR; Goldberg MS; Farberg AS; Trotter SC; Reed K; Brodland DG; Koyfman SA; Somani AK; Arron ST; Wysong A
Future Oncol; 2022 Mar; 18(7):833-847. PubMed ID: 34821148
[TBL] [Abstract][Full Text] [Related]
20. Incorporation of the 40-Gene Expression Profile (40-GEP) Test to Improve Treatment Decisions in High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients: Case Series and Algorithm.
Singh G; Tolkachjov SN; Farberg AS
Clin Cosmet Investig Dermatol; 2023; 16():925-935. PubMed ID: 37051586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
